Table 1.
Ongoing IL-13Rα2-targeted CAR T cell therapy clinical trials (from clinicaltrials.gov ).
| Study Title (Clinical Trial Identifier) |
Study Phase (# patients) |
Target Tumor | ROA | CAR T Cell (Reference) | IO Combination |
Sponsor | Results (Reference) |
|---|---|---|---|---|---|---|---|
| Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (NCT02208362) | Phase 1 (n=92) |
Refractory or recurrent HGG | IT, IC or ICV | Autologous IL13BBζ TCM-enriched T cells: IL13 (E13Y) zetakine/optimized hinge/41BB/truncated CD19 (67) | None | City of Hope Medical Center | 1 patient: regression of all intracranial and spinal tumors for 7.5 months (68) |
| IL13Rα2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM (NCT04003649) | Phase 1 (n=60) |
Resectable, recurrent GBM | ITV/ITC | Autologous IL13BBζ TCM-enriched T cells: IL13 (E13Y) zetakine/optimized hinge/41BB/truncated CD19 (67) | Ipilimumab, nivolumab | City of Hope Medical Center | No reported results |
| Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma (NCT04119024) | Phase 1 (n=24) |
Stage IIIC or IV Melanoma | IV | Autologous IL13BBζ TCM-enriched T cells: IL13 (E13Y) zetakine/optimized hinge/41BB/truncated CD19 (67) | IL-2 | UCLA Jonsson Comprehensive Cancer Center | No reported results |
| CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children (NCT04510051) | Phase 1 (n=18) |
Brain neoplasm | ICV | Autologous IL13BBζ TCM-enriched T cells: IL13 (E13Y) zetakine/optimized hinge/41BB/truncated CD19 (67) | None | City of Hope Medical Center | No reported results |
| Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma (NCT04661384) | Phase 1 (n=30) |
Leptomeningeal metastases | ICV | Autologous IL13BBζ TCM-enriched T cells: IL13 (E13Y) zetakine/optimized hinge/41BB/truncated CD19 (67) | None | City of Hope Medical Center | No reported results |
| CART-EGFR-IL13Rα2 in EGFR Amplified Recurrent GBM (NCT05168423) | Phase 1 (n=18) |
EGFR-amplified recurrent GBM (IDH wildtype) | IV | Autologous T cells co-expressing two CARs targeting cryptic EGFR epitope 806 and IL-13Rɑ2 | None | University of Pennsylvania | No reported results |
| Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas (NCT03423992) | N/A (n=100) |
Glioma | IV | Autologous CAR T cells (CAR not specified) | Anti-PD-L1 | Xuanwu Hospital | (69) (IL13Rɑ2 not published) |
CNS, central nervous system; CTL, cytotoxic T lymphocytes; GBM, glioblastoma; HGG, high grade glioma; IC, intracavitary; ICV, intracerebroventricular; IDH, isocitrate dehydrogenase 1; IO, immune-oncology; ITC, intracranial intratumoral; ITV, intracranial intraventricular; IV, intravenous; ROA, route of administration; TCM, central memory T cells.